Note on the use of browser cookies

Cookies are important to the proper functioning of a site. To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to optimize site functionality, and deliver content tailored to your interests.
Click "Agree and Proceed" to accept our cookies policy and go directly to the site or click on "Privacy Policy" to see detailed informations about the data protection of this website.

Head Navigation (EN)

MODAG - Neuroscience Solutions

MODAG GmbH - Overview

 

MODAG focuses on research and development of therapeutics and diagnostics for neurodegenerative diseases. It is a privately held company located at the Hochtechnologiepark Wendelsheim, Germany with additional Research & Development facilities in Munich and Göttingen. MODAG’s innovative approach offers a unique combination of early diagnosis and targeted disease-modifying therapies for severe neurological disorders.

MODAG´s collaborations with top-tier US and European research institutions, combined with the interdisciplinary research and development expertise of the founder´s and the management team, provide ideal conditions for the accelerated implementation into clinical applications. Built upon an extensive portfolio of patented active compounds, MODAG is developing a new oligomer modulator for Multiple System Atrophy (MSA) and other synucleinopathies such as Parkinson´s disease (PD) with the potential to deliver novel disease-modifying, first-in-class drugs with the potential to halt progression.

 

 

Management of MODAG

 

torsten matthias

Dr. Torsten Matthias, Chief Executive Officer
MODAG CEO Dr. Matthias has over twenty years of experience as Owner, CEO and CSO of the globally active Aesku.Group, a research-oriented manufacturer and distributor of novel products and services for the early detection, diagnosis and prognosis of autoimmunity, infectious serology, allergies and food intolerances. In recent years, the Aesku.Group and Dr. Matthias have received numerous awards for the innovative nature of the company and its products.

Dr. Matthias holds a Bachelor of Science in Chemistry and a PhD in Physical Biochemistry from the Technical University of Dresden, a PhD in Biochemistry and Genetic Engineering from the University of Bielefeld and has been featured in over 200 scientific publications. The primary objective of Dr. Matthias's research and development work is the advancement of innovative and market-oriented diagnostics and therapies.

In addition to driving competitive and successful companies, Dr. Matthias’s is highly involved in developing close networks and securing interdisciplinary research in pathogenesis, diagnosis and therapy of neuronal degenerative diseases.

 

 

armin giese neu

Prof. Dr. Armin Giese, Chief Scientific Officer
Prior to joining MODAG as CSO, Prof. Dr. Giese was Acting Head of Department at the Center for Neuropathology and Prion Research (ZNP) at the Ludwig Maximilian University of Munich and Acting Head of the German Reference Center for Neurodegenerative Diseases (DGNN).

He holds a Bachelor of Science from the University College London, Medical Licenses from the University of Kiel, and a Doctor of Medicine from the University of Göttingen. Dr. Giese is a board-certified neuropathologist at the Bavarian Chamber of Physicians (Landesärztekammer Bayern), and has published over 130 scientific publications that have been cited more than 12,000 times. His scientific work focuses on the role of protein aggregation in neurodegenerative diseases.

Prof. Dr. Giese developed new high-throughput methods for the detection of protein oligomers and for the screening of aggregation inhibitors based on single particle spectroscopy. Utilizing this technology, he identified novel aggregation inhibitors with excellent medical-chemical properties and high in vivo efficacy. Based on these findings, he co-founded MODAG GmbH in 2013.

 

 

Company History

 

In a cooperation with the teams of Prof. Dr. Armin Giese at the LMU Munich and Prof. Dr. Dr. h.c. Christian Griesinger at the Max Planck Institute for Biophysical Chemistry Göttingen, a new class of oligomer modulators was identified with an innovative screening platform based on single particle fluorescence technology (SIFT) was identified.

This drug development program led to the identification of anle138b and more than 250 analogs, which are protected by several patents. In addition to the non-dilutive financing through grants, MODAG successfully completed a first round of seed funding in 2013 with the participation of “Bayerische Patentallianz GmbH”, “Max Planck Innovation” and the founding partners Prof. Dr. Armin Giese, Prof. Dr. Christian Griesinger, Dr. Marcus Kostka and Dr. Torsten Matthias as the main investor of this seed financing.

Following the successful completion of the anle138b preclinical development program and the development of the associated diagnostic tools, MODAG has secured Series A financing in 2019 and is currently advancing lead program anle138b into Phase 1 clinical trial.

 

 

External concept validation

 

pergamon prize

Galenus-von-Pergamon Prize
Finalist of the Galenus von Pergamon Prize 2013

 

innovation prize 2013

Innovation Prize Universal Biotech 
Finalist of the Innovation Prize Universal Biotech Conference Paris 2011

 

f1000

F1000 Prime 
Recommended by Wolfgang Jahnke, July 2013 (Novartis Institute for Biomedical Research, Basel)
"I was surprised that a link exists with such properties, but I am also convinced of the data. It will be interesting to see the performance of the component in clinical trials..."